SH5 Stock Overview
Engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sotera Health Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.00 |
| 52 Week High | US$17.20 |
| 52 Week Low | US$9.90 |
| Beta | 2.06 |
| 11 Month Change | 8.91% |
| 3 Month Change | 1.85% |
| 1 Year Change | -35.67% |
| 33 Year Change | -47.10% |
| 5 Year Change | n/a |
| Change since IPO | -52.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| SH5 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.9% | 0.5% | -0.1% |
| 1Y | -35.7% | -15.9% | 2.3% |
Return vs Industry: SH5 underperformed the German Life Sciences industry which returned -15.9% over the past year.
Return vs Market: SH5 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| SH5 volatility | |
|---|---|
| SH5 Average Weekly Movement | 4.1% |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: SH5 has not had significant price volatility in the past 3 months.
Volatility Over Time: SH5's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 3,000 | Michael Petras | soterahealth.com |
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.
Sotera Health Company Fundamentals Summary
| SH5 fundamental statistics | |
|---|---|
| Market cap | €3.13b |
| Earnings (TTM) | €50.88m |
| Revenue (TTM) | €1.00b |
61.6x
P/E Ratio3.1x
P/S RatioIs SH5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SH5 income statement (TTM) | |
|---|---|
| Revenue | US$1.08b |
| Cost of Revenue | US$484.10m |
| Gross Profit | US$592.77m |
| Other Expenses | US$538.20m |
| Earnings | US$54.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.19 |
| Gross Margin | 55.05% |
| Net Profit Margin | 5.07% |
| Debt/Equity Ratio | 519.2% |
How did SH5 perform over the long term?
See historical performance and comparison